Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis.
Magnetic resonance imaging (MRI) provides an objective method of evaluating multiple sclerosis clinical trials and is at least five times more sensitive to disease activity. In a recent clinical trial, MRI was also approximately twice as sensitive as clinical measurements to the treatment effect of a drug.
Paty
D W
DW
Department of Medicine, University of British Columbia, Vancouver, Canada.
Li
D K
DK
Oger
J J
JJ
Kastrukoff
L
L
Koopmans
R
R
Tanton
E
E
Zhao
G J
GJ
D001921:Brain / Q000473:pathology*; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards*; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging / Q000592:standards / Q000706:statistics & numerical data; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology*; D010919:Placebos; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
D016898:Interferon-alpha; D010919:Placebos; D016899:Interferon-beta; D016572:Cyclosporine